Search Results

Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study.

• Authors : Koska, Juraj¹ (AUTHOR) ; Hu, Yueming² (AUTHOR); Furtado, Jeremy^3,4 (AUTHOR)

Subjects: *APOLIPOPROTEIN C; *GLUCOSE tolerance tests; *INSULIN sensitivity

• Source: Diabetes Care. Dec2024, Vol. 47 Issue 12, p2214-2222. 9p.

Record details

Glycation of Apolipoprotein C1 Impairs Its CETP Inhibitory Property: Pathophysiological Relevance in Patients With Type 1 and Type 2 Diabetes.

• Authors : Bouillet, Benjamin^1,2 ; Gautier, Thomas²; Blache, Denis²

Subjects: *APOLIPOPROTEIN C; *TREATMENT of diabetes; *PEOPLE with diabetes

• Source: Diabetes Care. Apr2014, Vol. 37 Issue 4, p1148-1156. 9p. 2 Charts, 2 Graphs.

Record details

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.

• Authors : Digenio, Andres; Dunbar, Richard L.; Alexander, Veronica J.

Subjects: APOLIPOPROTEINS; BLOOD lipoproteins; BLOOD plasma

• Source: Diabetes Care; Aug2016, Vol. 39 Issue 8, p1408-1415, 8p, 1 Chart, 3 Graphs

Record details

Dose-Dependent Effect of Rosuvastatin on VLDL-Apolipoprotein C-III Kinetics in the Metabolic Syndrome.

• Authors : Ooi, Esther M. M.; Watts, Gerald F.; Chan, Dick C.

Subjects: DRUG efficacy; STATINS (Cardiovascular agents); APOLIPOPROTEINS

• Source: Diabetes Care; Aug2008, Vol. 31 Issue 8, p1656-1661, 6p, 1 Diagram, 2 Charts

Record details

Atorvastatin Decreases Apolipoprotein C-lll in Apolipoprotein B-Containing Lipoprotein ana HDL in Type 2 Diabetes.

• Authors : Dallinga-Thie, Geesje M.; Berk-Planken, Ingrid I. L.; Bootsma, Aart H.

Subjects: APOLIPOPROTEINS; CELL receptors; CARDIOVASCULAR diseases

• Source: Diabetes Care; Jun2004, Vol. 27 Issue 6, p1358-1364, 7p, 2 Charts, 2 Graphs

Record details

Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.

• Authors : Dallinga-Thie, Geesje M; Berk-Planken, Ingrid I L; Bootsma, Aart H

• Source: Diabetes Care; Jun2004, Vol. 27 Issue 6, p1358-1364, 7p

Record details

1499-P: Apolipoprotein C-III as a Novel Predictor for T2D Incidence in Amerindians.

• Authors : HSUEH, WEN-CHI; WALTER, MARY; NELSON, ROBERT

• Source: Diabetes; 2019 Supplement, Vol. 68, pN.PAG-N.PAG, 1p

Record details

Glucose regulates the expression of the farnesoid X receptor in liver.

• Authors : Duran-Sandoval, Daniel; Mautino, Gisèle; Martin, Geneviève

Subjects: HYPERTRIGLYCERIDEMIA; GALLBLADDER diseases; DIABETES complications

• Source: Diabetes; Apr2004, Vol. 53 Issue 4, p890-898, 9p, 1 Black and White Photograph, 7 Graphs

Record details

NEW CONCEPTS AND TREATMENTS OF DIABETIC DYSLIPIDEMIA.

Subjects: GLUCAGON-like peptides; FATTY liver; TYPE 2 diabetes

• Source: Diabetes; 2015 Supplement, Vol. 64, pA66-A68, 3p, 2 Charts, 1 Graph

Record details

Hematopoietic NLRP3 and AIM2 Inflammasomes Promote Diabetes-Accelerated Atherosclerosis, but Increased Necrosis Is Independent of Pyroptosis.

• Authors : Hsu, Cheng-Chieh; Fidler, Trevor P.; Kanter, Jenny E.

Subjects: NLRP3 protein; TYPE 1 diabetes; PYROPTOSIS

• Source: Diabetes; Jul2023, Vol. 72 Issue 7, p999-1011, 13p

Record details